Two recent clinical trials (VEGF Trap-Eye: Investigation of Efficacy and Safety in CRVO (GALILEO)12, 13 and VEGF Trap-Eye for macular edema secondary to CRVO (COPERNICUS)14, 15) have shown that monthly intravitreal aflibercept treatment was well tolerated and improved visual acuity after 6 months significantly more than sham injections; these improvements were maintained with subsequent monthly monitoring and PRN dosing.12 Aflibercept was approved for the treatment of macular edema secondary to CRVO in September 2012.16 The gene discussed is VEGFA; the disease is macular retinal edema.